# 最高法院拒絕受理針對醫療保險藥品價格談判計畫的訴訟。

*biotech · news · 2026-05-18 · STAT*

## Key points

- 最高法院拒絕審理主要藥廠對醫療保險價格談判提出的訴訟。
- 阿斯利康、勃林格殷格翰、百時美施貴寶、楊森、諾華及諾和諾德提起訴訟。
- 在最高法院決定前，所有下級法院均裁定不利於藥廠。
- 最高法院的駁回實質上維持了醫療保險藥品價格談判計畫的運作。

WASHINGTON — The Supreme Court on Monday dealt a major blow to the brand drug industry’s legal campaign against the Medicare drug price negotiation program. The court declined to take up lawsuits against the program by AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Janssen, Novartis, and Novo Nordisk. The justices did not give a reason for their decision. Advertisement The rejection was not a surprise. The drugmakers lost their appeals in lower courts, and the Supreme Court typically does not take up cases when there is agreement among lower courts.

**Companies:** AstraZeneca, Bristol Myers Squibb, Novartis, Boehringer Ingelheim, Janssen, Novo Nordisk
**Countries:** United States

[Read the full story on STAT](https://www.statnews.com/2026/05/18/supreme-court-rejects-challenge-medicare-drug-price-negotiations/)

---

Canonical: https://newsio.io/zh-TW/n/b8caa199-79d3-4a73-95e6-92a42a150d78/
Summarized by Newsio from STAT. https://newsio.io/how-it-works